The connection between Cannabis sativa‘s chemical compounds and their ability to treat three different inflammatory ailments including bowel diseases, (IBD, e.g., Crohn's and ulcerative colitis), neuronal diseases (IND, e.g., Parkinson and Alzheimer), and a wide range of inflammatory skin diseases (ISD, e.g., atopic dermatitis and psoriasis) is presented. We review the range of experiments conducted over the last decade using either the whole extract of cannabis or separated mono-phytocannabinoids in the attempt to decipher the lead molecules, the receptors involved, the effects on genes and proteins, and especially the therapeutic potency of cannabis-derived compounds for treating these different inflammatory diseases. Along with the specifications for its current cutting-edge potential, the drawbacks and the designated needs for additional specific information from future research are indicated.
MechoulamR, GaoniY. (1965) Hashish—iv: The isolation and structure of cannabinolic, cannabidiolic and cannabigerolic acids. Tetrahedron, 21, 1223–1229.
2.
Aizpurua-OlaizolaO, SoydanerU, ÖztürkE, SchibanoD, SimsirY, NavarroP, EtxebarriaN, UsobiagaA. (2016) Evolution of the cannabinoid and terpene content during the growth of Cannabis sativa plants from different chemotypes. Journal of Natural Products, 79, 324–331.
3.
GrotenhermenF, RussoE. (2002) Cannabis and Cannabinoids-Pharmacology, Toxicology, and Therapeutic Potential. GrotenhermenF, (Eds.). Binghamton, New York. 55–65.
4.
CarliniEA. (2004) The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Δ9-THC) on humans. Toxicology, 44, 461–467.
5.
ZiasJE, StarkH, SeligmanJ, LevyR, WerkerE, BreuerA, MechoulamR. (1993) Early medical use of cannabis. Nature, 363, 215.
6.
MerrilleesRS. (1962) Opium trade in the Bronze Age Levant. Antiquity, XXXVI, 287–292.
7.
MerlinMD. (2003) Archaeological evidence for the tradition of psychoactive plant use in the Old World. Economical Botany, 57, 295–323.
8.
NamdarD, AmraniA, KletterR. (2015) Chapter 17: Scopolin in Iron Age juglets from the Philistine repository pit of Yavneh, In Yavneh II. KletterR., ZifferI., ZwickelW. (Eds). Orbis Biblicus et Orientalis, Academic Press, Fribourg. 214–223.
9.
GadotY, FinkelsteinI, IserlisM, MaeirAM, NahshoniP, NamdarD. (2014) Tracking down cult: production, function and content of chalices in Iron Age Philistia. Tel Aviv, 41, 54–75.
10.
PennacchioM, JeffersonLV, HavensK. (2010) Uses and Abuses of Plant-Derived Smoke: its Ethnobotany as Hallucinogen, Perfume, Incense, and Medicine. Oxford University Press, Oxford, 102.
11.
LynchME, CampbellF. (2011) Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology, 72, 735–744.
WilseyB, MarcotteT, TsodikovA, MillmanJ, BentleyH, GouauxB, FishmanS. (2008) A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. Journal of Pain, 9, 506–521.
14.
PorterBE, JacobsonC. (2013) Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behavior, 29, 574–577.
15.
SlatkinNE. (2007) Cannabinoids in the Treatment of Chemotherapy-Induced Nausea and Vomiting: Beyond Prevention of Acute Emesis. The Journal of Supportive Oncology, 5, Sup. 3, 1–9.
16.
KoganNM, MechoulamR. (2007) Cannabinoids in Health and Disease. Dialogues in Clinical Neuroscience, 9, 413–430.
17.
Corey-BloomJ, WolfsonT, GamstA, JinS, MarcotteTD, BentleyH, GouauxB. (2012) Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. Canadian Medical Association Journal, 10, 1143–1150.
18.
MestreL, CorreaF, DocagneF, Ortega-GuitiérrezS, Arévalo-MartínA, Molina-HolgadoE, BorrellJ, GuazaC. (2006) Cannabinoid system and neuroinflammation: therapeutic perspectives in multiple sclerosis. Revue Neurologique, 43, 541–548.
19.
RogDJ, NurmikkoTJ, FriedeT, YoungCA. (2005) Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology, 65, 812–819.
20.
WadeDT, MakelaP, RobsonP, HouseH, BatemanC. (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis, 10, 434–441.
21.
TomidaI, PertweeRG, Azuara-BlancoA. (2004) Cannabinoids and glaucoma. British Journal of Ophthalmology, 88, 708–713.
22.
TashkinDP, ShapiroBJ, FrankIM. (1974) Acute effects of smoked marijuana and oral delta 9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. The American Review of Respiratory Disease, 109, 420–428.
23.
ElSohlyMA, SladeD. (2005) Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Science, 78, 539–548.
24.
MechoulamR, ParkerLA, GallilyR. (2002) Cannabidiol: An overview of some pharmacological aspects. Journal of Clinical Pharmacology, 42, 11S–19S.
25.
MechoulamR, ShaniA, EderyH, GrunfeldY. (1970) Chemical basis of hashish activity. Science, 169, 611–612.
26.
RadwanMM, ElSohlyMA, SladeD, AhmedSA, WilsonL, El-AlfyAT, KhanIA, RossSA. (2008) Non-cannabinoid constituents from a high potency Cannabis sativa variety. Phytochemistry, 69, 2627–2633.
27.
AppendinoG, GianaA, GibbonsS, MaffeiM, GnaviG, GrassiG, SternerO. (2008) A polar cannabinoid from Cannabis sativa var. Carma. Natural Product Communications, 3, 1977–1980.
AhmedSA, RossSA, SladeD, RadwanMM, KhanIA, ElSohlyMA. (2008) Structure determination and absolute configuration of cannabichromanone derivatives from high potency Cannabis sativa. Tetrahedron Letters, 49, 6050–6053.
30.
MatsudaLA, LolaitSJ, BrownsteinMJ, YoungAC, BronnerTI. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561–564.
31.
MunroS, ThomasKL, Abu-ShaarM. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61–65.
32.
GrotenhermenF, RussoE. (2004) Pharmacology of cannabinoids. Neuroendocrinology Letters, 25, 14–23.
33.
BreivogelCS, GriffinG, Di MarzoV, MartinBR. (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Molecular Pharmacology, 60, 155–63.
34.
FrideE, FooxA, RosenbergE, FaigenboimM, CohenV, BardaL, BlauH, MechoulamR. (2003) Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a “CB3” receptor. European Journal of Pharmacology, 461, 27–34.
35.
Di MarzoV, HillMP, BisognoT, CrossmanAR, BrotchieJM. (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson‘s disease. The Official Journal of the Federation of American Societies for Experimental Biology, 14, 1432–1438.
36.
WileyJL, MartinBR. (2002) Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chemistry and Physics of Lipids, 121, 57–63.
37.
RussoEB. (2011) Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163, 1344–1364.
38.
SartorRB. (2006) Mechanisms of disease: Pathogenesis of Crohn's disease and ulcerative colitis. Nature Reviews Gastroenterology Hepatology, 3, 390–407.
39.
RuhaakLR, FelthJ, KarlssonPC, RafterJJ, VerpoorteR, BohlinL. (2011) Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. Biological and Pharmaceutical Bulletin, 34, 774–778.
40.
SturmA, DignassAU. (2008) Epithelial restitution and wound healing in inflammatory bowel disease. World Journal of Gastroenterology, 14, 348.
41.
D'HaensGR, SartorRB, SilverbergMS, PeterssonJ, RutgeertsP. (2014) Future directions in inflammatory bowel disease management. Journal of Crohns Colitis, 8, 726–734.
42.
IzzoAA, CamilleriM. (2009) Cannabinoids in intestinal inflammation and cancer. Pharmacological Research, 60, 117–125.
43.
SchichoR, StorrM. (2013) Cannabis finds its way into treatment of Crohn's disease. Pharmacology, 93, 1–3.
44.
NaftaliT, LevLB, YablecovitchD, HalfE, KonikoffFM. (2011) Treatment of Crohn's disease with cannabis: An observational study. Israel Medical Association Journal, 13, 455–458.
45.
NaftaliT, SchleiderLB, DotanI, LanskyEP, BenjaminovFS, KonikoffFM. (2013) Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clinical Gastroenterology Hepatology, 11:1276–1280.
46.
WrightK, DuncanM, SharkeyK. (2008) Cannabinoid CB2 receptors in the gastrointestinal tract: A regulatory system in states of inflammation. British Journal of Pharmacology, 153, 263–270.
47.
StorrMA, KeenanCM, ZhangH, PatelKD, MakriyannisA, SharkeyKA. (2009) Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflammatory Bowel Disease, 15, 1678–1685.
48.
RybergE, LarssonN, SjögrenS, HjorthS, HermanssonNO, LeonovaJ, ElebringT, NilssonK, DrmotaT, GreasleyP. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology, 152, 1092–1101.
49.
StančićA, JandlK, HasenöhrlC, ReichmannF, MarscheG, SchuligoiR, HeinemannA, StorrM, SchichoR. (2015) The GPR55 antagonist CID16020046 protects against intestinal inflammation. Neurogastroenterology and Motility, 27, 1432–1445.
50.
GreineisenWE, TurnerH. (2010) Immunoactive effects of cannabinoids: Considerations for the therapeutic use of cannabinoid receptor agonists and antagonists. International Immunopharmacology, 10, 547–555.
ZuardiAW, ShirakawaI, FinkelfarbE, KarniolIG. (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology, 6, 245–50.
53.
CostaB, ParolaroD, ColleoniM. (1996) Chronic cannabinoid, CP-55,940, administration alters biotransformation in the rat. European Journal of Pharmacology, 313, 17–24.
54.
BisognoT, HanusL, De PetrocellisL, TchilibonS, PondeDE, BrandiI, MorielloAS, DavisJB, MechoulamR, Di MarzoV. (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology, 134, 845–52.
55.
MechoulamR, HanušL. (2002) Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chemistry and physics of lipids, 121, 35–43.
56.
BornheimLM, GrilloMP. (1998) Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Chemistry Research of Toxicology, 11, 1209–1216.
57.
JaggarSI, HasnieFS, SellaturayS, RiceAS. (1998) The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain, 76, 189–99.
58.
AgurellS, CarlssonS, LindgrenJE, OhlssonA, GillespieH, HollisterL. (1981) Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia, 37, 1090–1092.
59.
HuntCA, JonesRT, HerningRI, BachmanJ. (1981) Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. Journal of Pharmacokinetic and Biopharmacology, 9, 245–60.
60.
PaganoE, CapassoR, PiscitelliF, RomanoB, ParisiOA, FinizioS, LauritanoA, Di MarzoV, IzzoAA, BorrelliF. (2016) An orally active cannabis extract with high content in cannabidiol attenuates chemically-induced intestinal inflammation and hypermotility in the mouse. Frontiers in Pharmacology, 7, 341.
61.
HillTDM, CascioMG, RomanoB, DuncanM, PertweeRG, WilliamsCM, WhalleyBJ, HillAJ. (2013) Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. British Journal of pharmacology, 170, 679–692.
62.
CastanedaFE, WaliaB, Vijay–KumarM, PatelNR, RoserS, KolachalaVL, RojasM, WangL, OpreaG, GargP, GewirtzAT. (2005) Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology, 129, 1991–2008.
63.
BorrelliF, FasolinoI, RomanoB, CapassoR, MaielloF, CoppolaD, OrlandoP, BattistaG, PaganoE, Di MarzoV, IzzoAA. (2013) Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 85, 1306–1316.
64.
IhenetuK, MollemanA, ParsonsME, WhelanCJ. (2003) Inhibition of Interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. European Journal of Pharmacology, 458, 207–215.
65.
NallathambiR, MazuzM, IonA, SelvarajG, WeiningerS, FridlenderM, NasserA, SageeO, KumariP, NemichenizerD, MendelovitzM.FirsteinN, HaninO, KonikoffF, KapulnikY, NaftaliT, KoltaiH. (2017) Anti-inflammatory activity in colon models is derived from Δ9-Tetrahydrocannabinolic Acid that interacts with additional compounds in cannabis extracts. Cannabis and Cannabinoid Research, 2, 167–182.
66.
MaccarroneM, BattistaN, CentonzeD. (2007) The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases. Progress in Neurobiology, 81, 349–379.
67.
BrotchieJM. (2003) CB1 cannabinoid receptor signalling in Parkinson's disease. Current Opinion in Pharmacology, 3, 54–61.
68.
PisaniA, FezzaF, GalatiS, BattistaN, NapolitanoS, Finazzi-AgroA, BernardiG, BrusaL, PierantozziM, StanzioneP, MaccarroneM. (2005) High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Annals of Neurology, 57, 777–779.
69.
KreitzerAC, MalenkaRC. (2007) Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature, 445, 643–647.
70.
SieradzanKA, FoxSH, HillM, DickJPR, CrossmanAR, BrotchieJM. (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology, 57, 2108–2111.
71.
CarrollCB, BainPG, TeareL, LiuX, JointC, WroathC, ParkinSG, FoxP, WrightD, HobartJ, ZajicekJP. (2004) Cannabis for dyskinesia in Parkinson's disease: a randomized double-blind crossover study. Neurology, 63, 1245–1250.
72.
del ValleAA. (2006) Implication of cannabinoids in neurological diseases. Cellular and Molecular Neurobiology, 26, 577–589.
73.
Lastres-BeckerI, Fernandez-RuizJ. (2006) An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments. Current Medical Chemistry, 13, 3705–3718.
74.
Garcia-ArencibiaM, GarciaC, Fernandez-RuizJ. (2009) Cannabinoids and Parkinson Disease. CNS Neurological Disorder Drug Targets, 8, 432–439.
75.
RitchieK, KildeaD. (1990) Is senile dementia “age-related” or “ageing-related”? - evidence from meta-analysis of dementia prevalence in the oldest old. Lancet, 346, 931–934.
76.
RozemullerJM, EikelenboomP, PalsST, StamFC. (1989) Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. Neuroscience Letters, 101, 288–292.
77.
BachurinSO. (2003) Medicinal chemistry approaches for the treatment and prevention of Alzheimer's disease. Medical Research Review, 23, 48–88.
78.
InestrosaNC, AlvarezA, PerezCA, MorenoRD, VicenteM, LinkerC, CasanuevaOI, SotoC, GarridoJ. (1996) Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron, 16, 881–891.
79.
AlvarezA, AlarcónR, OpazoC, CamposEO, MuñozFJ, CalderónFH, DajasF, GentryMK, DoctorBP, De MelloFG, InestrosaNC. (1998) Stable complexes involving acetylcholinesterase and amyloid-β peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. Journal of Neuroscience, 18, 3213–3223.
80.
BartoliniM, BertucciC, CavriniV, AndrisanoV. (2003) β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochemical Pharmacology, 65, 407–416.
81.
DickersonBC, SalatDH, GreveDN, ChuaEF, Rand-GiovannettiE, RentzDM, BertramL, MullinK, TanziRE, BlackerD, AlbertMS. (2005) Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology, 65, 404–411.
82.
Carmo CarreirasM, MendesE, Jesus PerryM, Paula FranciscoA, Marco-ContellesJ. (2013) The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Current Topics in Medicinal Chemistry, 13, 1745–1770.
83.
EubanksLM, RogersCJ, BeuscherAEIV, KoobGF, OlsonAJ, DickersonTJ, JandaKD. (2006) A molecular link between the active component of marijuana and Alzheimer's disease pathology. Molecular Pharmaceutics, 3, 773–777.
84.
CasanovaML, BlázquezC, Martínez-PalacioJ, VillanuevaC, Fernández-AceñeroMJ, HuffmanJW, JorcanoJL, GuzmánM. (2003) Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. The Journal of Clinical Investigation, 111, 43–50.
85.
BíróT, TóthBI, HaskóG, PausR, PacherP. (2009) The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trend in Pharmacological Sciences, 30, 411–420.
86.
WilkinsonJD, WilliamsonEM. (2007) Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. Journal of Dermatological Sciences, 45, 87–92.
87.
ParadisiA, PasquarielloN, BarcaroliD, MaccarroneM. (2008) Anandamide regulates keratinocyte differentiation by inducing DNA methylation in a CB1 receptor-dependent manner. Journal of Biological Chemistry, 283, 6005–6012.
88.
BlázquezC, CarracedoA, BarradoL, RealPJ, Fernández-LunaJL, VelascoG, MalumbresM, GuzmánM. (2006) Cannabinoid receptors as novel targets for the treatment of melanoma. The FASEB journal, 20, 2633–2635.
89.
DobrosiN, TóthBI, NagyG, DózsaA, GéczyT, NagyL, ZouboulisCC, PausR, KovácsL, BíróT. (2008) Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling. The FASEB Journal, 22, 3685–3695.
90.
PulvirentiN, NascaMR. MicaliG. (2007) Topical adelmidrol 2% emulsion, a novel aliamide, in the treatment of mild atopic dermatitis in pediatric subjects: a pilot study. Acta Dermatovenerologica Croatica, 15, 80–83.
91.
LambertDM. (2007) Allergic contact dermatitis and the endocannabinoid system: from mechanisms to skin care. ChemMedChem, 2, 1701–1702.
PucciM, RapinoC, Di FrancescoA, DaineseE, D'AddarioC, MaccarrM. (2013) Epigenetic control of skin differentiation genes by phytocannabinoids. British Journal of Pharmacology, 170, 581–591.
